Table 1.
Characteristics of outpatient kidney transplant recipients with known coronavirus disease 2019 versus suspected coronavirus disease 2019
| Characteristic | n (%) or Median (IQR) | ||
|---|---|---|---|
| All | Suspected COVID-19 (PUI) | Known COVID-19 | |
| n | 41 | 19 (46) | 22 (54) |
| Men | 30 (73) | 13 (68) | 17 (77) |
| Age, yr | 49 (41–63) | 49 (38–62) | 52 (42–64) |
| Time since transplant, mo | 42 (18–66) | 39 (18–61) | 43 (17–98) |
| Deceased donor kidney recipient | 23 (56) | 12 (63) | 11 (50) |
| Hypertension | 37 (90) | 17 (89) | 20 (91) |
| Diabetes mellitus | 11 (27) | 5 (26) | 6 (27) |
| Body mass index, kg/m2 | 26.6 (25.7–32.0) | 27.5 (24.8–32.5) | 26.5 (25.8–27.9) |
| Obese, body mass index ≥30 kg/m2 | 12 (29) | 7 (37) | 5 (22) |
| Angiotensin-converting enzyme inhibitor use | 3 (7) | 2 (11) | 1 (5) |
| Angiotensin receptor blocker use | 6 (15) | 1 (5) | 5 (22) |
| Maintenance immunosuppression | |||
| Calcineurin inhibitor | 31 (76) | 16 (84) | 15 (68) |
| Mycophenolate mofetil/mycophenolate sodium | 31 (76) | 14 (74) | 17 (77) |
| Belatacept | 9 (22) | 3 (16) | 6 (27) |
| Prednisone | 16 (39) | 7 (37) | 9 (41) |
| Azathioprine | 5 (12) | 4 (21) | 1 (5) |
| Known sick contact | 21 (51) | 13 (68) | 8 (36) |
| Symptoms | |||
| Fever | 33 (80) | 11 (58) | 22 (100) |
| Cough | 23 (56) | 14 (74) | 9 (41) |
| Dyspnea (exertional or rest) | 16 (39) | 6 (32) | 10 (45) |
| Gastrointestinal | 11 (27) | 6 (32) | 5 (23) |
| Myalgia/arthralgia | 11 (27) | 7 (37) | 4 (18) |
| Fatigue/malaise | 10 (24) | 8 (36) | 2 (11) |
| Headache | 3 (7) | 1 (5) | 2 (9) |
| Chills | 2 (5) | 0 (0) | 2 (9) |
| Symptoms improved as outpatient | 23 (56) | 15 (79) | 8 (36) |
| Admitted to hospital | 13 (32) | 1 (5) | 12 (55) |
IQR, interquartile range; COVID-19, coronavirus disease 2019; PUI, person under investigation.